- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07940010
Effects of Creatine Formulations on Exercise and Cognitive Performance
Effects of Creatine Monohydrate Versus a Multi-Ingredient Creatine Formulation on Exercise Performance, Cognitive Function, Hydration, and Gastrointestinal Tolerability
This study will examine whether a multi-ingredient creatine supplement produces different effects on exercise performance, cognitive function, hydration, and gastrointestinal symptoms compared with creatine monohydrate alone.
Approximately 16 healthy, physically active adults aged 18-40 years will participate. Each participant will take creatine monohydrate (5 grams per day) for 18 days and a multi-ingredient supplement containing creatine monohydrate (5 grams), sodium, potassium, magnesium, and taurine for another 18 days. The order of supplementation will be randomly assigned, with a 30-day break between conditions.
Participants will complete laboratory testing before and after each supplementation period. Testing will include bench press exercise to assess muscular endurance, repeated high-intensity cycling tests to assess exercise performance, and a computerized cognitive task to measure attention and reaction time. Researchers will also assess hydration, selected blood markers, perceived exertion, and gastrointestinal symptoms.
The findings may help determine whether adding electrolytes and taurine to creatine provides additional benefits or produces different physiological responses compared with creatine monohydrate alone.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Terence A Moriarty
- Numéro de téléphone: 319-273-6866
- E-mail: terence.moriarty@uni.edu
Lieux d'étude
-
-
Iowa
-
Cedar Falls, Iowa, États-Unis, 50614
- Recrutement
- Wellness and Recreation Center
-
Contact:
- Terence A Moriarty
- Numéro de téléphone: 319-273-6866
- E-mail: terence.moriarty@uni.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Adults aged 18-40 years.
- Apparently healthy individuals who are physically active and capable of performing vigorous exercise.
- Willing and able to complete repeated maximal-intensity cycling tests, bench press exercise, and cognitive assessments.
- Willing to consume both assigned dietary supplement formulations for 18 days each, separated by a 30-day washout period.
- Willing to refrain from taking additional creatine or electrolyte supplements during the study, including the washout period.
- Able and willing to provide written informed consent.
Exclusion Criteria:
- History of cardiovascular, metabolic, renal, neurological, or musculoskeletal conditions that may contraindicate vigorous exercise or interfere with study outcomes.
- Current injury or physical limitation that would prevent safe completion of the exercise testing procedures.
- Current pregnancy or plans to become pregnant during the study.
- Recent creatine supplementation prior to enrollment.
- Current use of medications or dietary supplements that may interfere with creatine metabolism, hydration status, exercise performance, cognitive function, or participant safety.
- Known allergy, intolerance, or contraindication to any ingredient in the study supplements.
- Unwillingness or inability to comply with supplementation, washout, or laboratory testing requirements.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Creatine Monohydrate Followed by Multi-Ingredient Creatine
Participants will receive creatine monohydrate (5 g/day) with sugar-free flavoring for 18 consecutive days, followed by a 30-day washout period. Participants will then receive a multi-ingredient formulation containing creatine monohydrate (5 g/day), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) for an additional 18 days. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after each supplementation period. |
Participants will consume 5 g/day of creatine monohydrate mixed with sugar-free flavoring for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period. Participants will consume a multi-ingredient dietary supplement containing creatine monohydrate (5 g), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) daily for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period. |
|
Expérimental: Multi-Ingredient Creatine Followed by Creatine Monohydrate
Participants will receive a multi-ingredient formulation containing creatine monohydrate (5 g/day), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) for 18 consecutive days, followed by a 30-day washout period. Participants will then receive creatine monohydrate (5 g/day) with sugar-free flavoring for an additional 18 days. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after each supplementation period. |
Participants will consume 5 g/day of creatine monohydrate mixed with sugar-free flavoring for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period. Participants will consume a multi-ingredient dietary supplement containing creatine monohydrate (5 g), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) daily for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Total Bench Press Repetitions
Délai: Baseline and Day 18 of each supplementation period.
|
Total number of repetitions completed across three sets of bench press exercise at 70% of baseline one-repetition maximum (1RM), performed to volitional fatigue with one minute of rest between sets. |
Baseline and Day 18 of each supplementation period.
|
|
Peak Power During Repeated Wingate Tests
Délai: Baseline and Day 18 of each supplementation period.
|
Peak power output (watts) measured during three consecutive 30-second Wingate cycling tests, performed with standardized recovery periods. |
Baseline and Day 18 of each supplementation period.
|
|
Mean Power During Repeated Wingate Tests
Délai: Baseline and Day 18 of each supplementation period.
|
Mean power output (watts) measured during each of three 30-second maximal-effort Wingate cycling tests. |
Baseline and Day 18 of each supplementation period.
|
|
Total Work During Repeated Wingate Tests
Délai: Baseline and Day 18 of each supplementation period.
|
Total mechanical work (kilojoules) completed across three 30-second Wingate cycling tests. |
Baseline and Day 18 of each supplementation period.
|
|
Stroop Interference Reaction Time
Délai: Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).
|
Cognitive performance assessed using a computerized Stroop task completed before exercise and during recovery between repeated Wingate tests. Reaction time (milliseconds) will be used to evaluate changes in cognitive performance as exercise-induced fatigue accumulates. |
Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).
|
|
Stroop Task Accuracy
Délai: Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).
|
Percentage of correct responses during a computerized Stroop task administered before exercise and during recovery between repeated Wingate cycling tests. |
Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Wingate Fatigue Index
Délai: Baseline and Day 18 of each supplementation period.
|
Percentage decline in power output during repeated Wingate tests. |
Baseline and Day 18 of each supplementation period.
|
|
Rating of Perceived Exertion
Délai: Baseline and Day 18 of each supplementation period.
|
Perceived exertion assessed using the Borg 6-20 scale following each Wingate. |
Baseline and Day 18 of each supplementation period.
|
|
Blood Lactate Concentration
Délai: Baseline and Day 18 of each supplementation period.
|
Blood lactate concentration (mmol/L) measured following each Wingate. |
Baseline and Day 18 of each supplementation period.
|
|
Urine Specific Gravity
Délai: Baseline and Day 18 of each supplementation period.
|
Urine specific gravity assessed before and after exercise to evaluate hydration status. |
Baseline and Day 18 of each supplementation period.
|
|
Blood Sodium Concentration
Délai: Baseline and Day 18 of each supplementation period.
|
Sodium concentration measured using an i-STAT analyzer. |
Baseline and Day 18 of each supplementation period.
|
|
Blood Potassium Concentration
Délai: Baseline and Day 18 of each supplementation period.
|
Potassium concentration measured using an i-STAT analyzer. |
Baseline and Day 18 of each supplementation period.
|
|
Gastrointestinal Symptom Severity
Délai: Baseline and Day 18 of each supplementation period.
|
Daily 0-10 ratings of bloating, abdominal discomfort, nausea, diarrhea, constipation, reflux, and overall gastrointestinal discomfort. |
Baseline and Day 18 of each supplementation period.
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IRB-FY27-58
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .